Rahul Bhargava, Director and Head of Hematology, Hematocology, and Stem Cell Transplant at Fortis Health Care, shared a post on LinkedIn:
“This is how we report our MRD at 10⁻⁶ sensitivity for Myeloma and Acute lymphoblastic leukemia giving us deeper insights into the disease:
- Whether to intensify therapy
- Whether to stop treatment
- Whether to switch or modify the regimen
For deeper interpretation and genomic correlations, Shrinidhi Nathany will help
MRD assays help detect and possibly eliminate even the last remaining malignant cells, preventing early relapse and guiding truly personalized care.
Fortis Healthcare we remain a Center of Excellence for Myeloid, Lymphoma, and Myeloma.”
More posts featuring Rahul Bhargava on OncoDaily.